Lumos Diagnostics welcomes Doug Ward as CEO

– USA, FL – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care diagnostic technologies, today announced the appointment of Doug Ward as CEO.

“We are delighted to welcome Doug Ward as the CEO of Lumos,” said Executive Chair, Sam Lanyon. “He is a proven leader in the healthcare industry and this role will leverage his vast experience, which spans notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic.”

About Doug Ward

Doug Ward has held executive positions including CEO during his more than 30-year career. Most recently he served as VP, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women’s healthcare to improve clinical results. Before joining Hologic, Mr. Ward was the CEO of Personal Genome Diagnostics where he led the organization’s transformation from a clinical laboratory testing service into a fully functional molecular in vitro diagnostics company.

“I am thrilled to join the talented team at Lumos Diagnostics,” said Doug Ward. “The assay development and manufacturing expertise at Lumos is impressive and presents significant growth potential by providing assay R&D for some of the world’s top medical technology companies, as well as developing and commercializing an emerging portfolio of Lumos-branded point-of-care tests.”

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team